葛根素联合二甲双胍治疗NAFLD合并2型糖尿病前期患者初步临床研究

doi:10.3969/j.issn.1672-5069.2018.03.023

摘要/Abstract

摘要： 目的探讨葛根素联合二甲双胍治疗非酒精性脂肪性肝病（NAFLD）合并糖尿病前期患者的临床效果。方法 2014年4月~2017年6月我院收治的84例NAFLD合并糖尿病前期患者,被随机分为对照组42例和观察组42例,分别给予盐酸二甲双胍片或二甲双胍联合葛根素治疗,观察3 m。常规检测血C反应蛋白（CRP）、丙二醛（MDA）、超氧化物歧化酶（SOD）、白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）。结果治疗后,观察组空腹血糖、餐后2 h血糖、胰岛素和HOMA-IR水平均显著低于对照组[分别为（5.92±0.51） mmol/L、（6.01±0.81） mmol/L、（5.90±0.62） mmol/L和（1.52±0.42）对（6.32±0.35） mmol/L、（6.39±0.71） mmol/L、（6.72±0.83） mmol/L和（1.71±0.39）,P<0.05];血TC、TG、LDL-C显著低于对照组[分别为（4.15±0.14） mmol/L、（1.12±0.22） mmol/L、（1.91±0.12） mmol/L 对（4.56±0.21） mmol/L、（1.31±0.13） mmol/L、（2.14±0.11） mmol/L],HDL-C显著高于对照组[（1.31±0.22） mmol/L对（1.11±0.09） mmol/L,P<0.05];AST和ALT显著低于对照组[分别为（分别为（49.71±4.75）U/L和（52.16±4.93） U/L 对（59.13±4.30） U/L和（77.52±7.15）U/L,P<0.05];血清炎症因子水平也显著低于对照组（P<0.05）。结论葛根素联合二甲双胍治疗NAFLD合并糖尿病前期患者疗效显著,可能与调节血糖和血脂代谢,改善肝功能有关。

关键词: 非酒精性脂肪性肝病, 糖尿病前期, 二甲双胍, 葛根素, 治疗

Abstract: Objective To investigate the clinical efficacy of puerarin combined with metformin in the treatment of patients with non-alcoholic fatty liver disease （NAFLD） and prediabetes. Methods 84 patients with NAFLD and prediabetes were recruited in our hospital between April 2014 and June 2017,and they were randomly divided into the control group（n=42） and the observation grou （n=42）,receiving metformin hydrochloride or combination of metformin and puerarin,a herbal medicine,respectively. Fasting blood glucose （FBG）,postprandial 2h blood glucose（2hPG）,glycosylated hemoglobin （HbA1c）,fasting insulin （FINS）,insulin resistance index（HOMA-IR）],and C reactive protein（CRP）,malondialdehyde（MDA）,superoxide dismutase （SOD）,interleukin-6（IL-6）,and tumor necrosis factor α（TNF- α）] were assayed. Results At the end of 3 month observation,blood levels of FBG, 2hPG, FINS and HOMA-IR in the observation group were lower than those in the control group[（5.92±0.51） mmol/L,（6.01±0.81） mmol/L,（5.90±0.62）mmol/L,（1.52±0.42） vs. （6.32±0.35） mmol/L,（6.39±0.71） mmol/L,（6.72±0.83） mmol/L,（1.71±0.39）,respectively,P<0.05];plasma levels of TC,TG and LDL-C in the observation group were lower than those in the control group[（4.15±0.14）mmol/L,（1.12±0.22） mmol/L,（1.91±0.12） mmol/L vs.（4.56±0.21） mmol/L,（1.31±0.13） mmol/L,（2.14±0.11） mmol/L],while HDL-C level was higher than that in the control group [（1.31±0.22） mmol/L vs. （1.11±0.09） mmol/L,P<0.05];serum AST and ALT levels in the observation group were much lower than those in the control group [（49.71±4.75） U/L and（52.16±4.93） U/L vs. （59.13± 4.30） U/L and （77.52 ±7.15） U/L,P<0.05];serum inflammationary cytokine levels were also lower than those in the control （P<0.05）. Conclusion Puerarin combined with metformin is effective in the treatment of patients with NAFLD and prediabetes, which might be related to the regulation of blood glucose and lipid metabolism, and improvement of the liver function.

Key words: Non-alcoholic fatty liver disease, Prediabetes, Puerarin, Metformin, Therapy

赵文涛, 曹高峰, 焦小红, 马辰辰, 林苗. 葛根素联合二甲双胍治疗NAFLD合并2型糖尿病前期患者初步临床研究[J]. 实用肝脏病杂志, 2018, 21(3): 409-412.

Zhao Wentao, Cao Gaofeng, Jiao Xiaohong, et al. Efficacy of puerarin combined with metformin in the treatment of patients with non-alcoholic fatty liver disease and prediabetes[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 409-412.

参考文献

[1] 胡跃霜,钟兴,潘天荣. 艾塞那肽治疗2型糖尿病合并NAFLD患者的疗效观察. 安徽医科大学学报,2017,52(4):546-549.
[2] 郭伟,高明松,彭聪,等. 利拉鲁肽联合二甲双胍对2型糖尿病合并NAFLD病肝脂肪变的影响. 中国现代医学杂志,2016,26(13):107-111.
[3] 阮勇,谭擎缨,阮芸,等. 二甲双胍治疗2型糖尿病合并非酒精性脂肪性肝病的临床观察. 中国药房,2015,26(33):4659-4661.
[4] 杨帆,李钶,蒋晓岚,等. 利拉鲁肽对肥胖2型糖尿病合并NAFLD患者的肝脏脂肪沉积的影响研究. 重庆医学,2016,45(25):3493-3495.
[5] 方新华,卢晓,吴国清. 葛根素对妊娠期糖尿病大鼠调节血脂和抗氧化作用的实验研究. 中华中医药学刊,2016,34(6):1504-1507.
[6] Chon YE,Kim KJ,Jung KS,et al.The relationship between type 2 diabetes mellitus and non-alcoholic fatty liver disease measured by controlled attenuation parameter. Yonsei Med J,2016,57(4):885-892.
[7] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 实用肝脏病杂志,2007,10(1):1-3.
[8] Yamazaki H,Tsuboya T,Tsuji K,et al.Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care,2015,38(9):1673.
[9] 王成剑,黄荣曦,姜英松,等. DPP-4抑制剂沙格列汀对糖尿病NAFLD的作用研究. 重庆医学,2017,46(11):1490-1491.
[10] Hallsworth K,Thoma C,Hollingsworth KG,et al.Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease:a randomized controlled trial. Clin Sci (Lond),2015,129(12):1097.
[11] 周步高,邹勇,王馨,等. 葛根素对损伤后肝细胞再生障碍大鼠的肝保护作用评价. 中华中医药杂志,2017,32(5):2046-2047.
[12] 赵月蓉,侯碧玉,张莉,等. 葛根素对实验性肝损伤的治疗作用研究进展. 中国新药杂志,2017,26(9):1005-1010.
[13] 李笠,梁学亚. 水飞蓟宾葡甲胺联合多烯磷脂酰胆碱治疗酒精性脂肪肝患者初步临床研究. 实用肝脏病杂志,2017,20(4):412-415.
[14] 赵文霞,张丽慧. 合理应用中成药治疗NAFLD. 实用肝脏病杂志,2017,20(2):132-134.
[15] Gawrieh S,Chalasani N.Pharmacotherapy for nonalcoholic fatty liver disease. Semin Liver Dis,2015,35(3):338.
[16] Lee YH,Kim JH,Kim SR,et al.Lobeglitazone,a novel thiazolidinedione,improves non-alcoholic fatty liver disease in type 2 diabetes:Its efficacy and predictive factors related to responsiveness. J Korean Med Sci,2017,32(1):60.
[17] Abruzzese GA,Motta AB.Nonalcoholic fatty liver disease in children and adolescents-Relationship with polycystic ovary syndrome. Curr Pharm Des,2015,21(35):5144.
[18] Kwok R,Choi KC,Wong GL,et al.Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements:a prospective cohort study. Gut,2016,65(8):1359-1368.
[19] Selvakumar PK,Kabbany MN,Lopez R,et al.Reduced lysosomal acid lipase activity-a potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients. Dig Liver Dis,2016,48(8):909-913.